Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 06/24/20
End: 07/15/24
Due: 07/15/25
Phase: N/A
Priority: Normal
Start: 08/22/24
End: 03/27/27
Due: 03/27/28
Phase: N/A
Priority: Normal
Start: 01/21/23
End: 09/30/27
Due: 09/30/28
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors | NCT04319757 | Acepodia Biotech, Inc. | user2@example.com | None | 2020-06-24 | 2024-07-15 | 2025-07-15 | - | - | 2025-07-14 |
| ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) | NCT06415487 | Acepodia Biotech, Inc. | user2@example.com | None | 2024-08-22 | 2027-03-27 | 2028-03-27 | - | - | 2025-07-14 |
| ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies | NCT05653271 | Acepodia Biotech, Inc. | user2@example.com | None | 2023-01-21 | 2027-09-30 | 2028-09-30 | - | - | 2025-07-14 |